Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows how streptococcal bacteria can be used to fight colon cancer

21.05.2014

Researchers at Western University (London, Canada) have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer.


Western University researchers Dr. David Hess and Dr. John McCormick and lead author Kelcey Patterson show how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumor cells, they are forcing the immune system to recognize and attack the cancer.

Credit: Schulich School of Medicine & Dentistry, Western University

By engineering a streptococcal bacterial toxin to attach itself to tumour cells, they are forcing the immune system to recognize and attack the cancer.

Kelcey Patterson, a PhD Candidate at Western and the lead author on the study, showed that the engineered bacterial toxin could significantly reduce the size of human colon cancer tumours in mice, with a drastic reduction in the instances of metastasis. By using mouse models that are stripped of their immune system, they were able to create a 'humanized mouse' – one that would not only grow human colon cancer cells, but would also support a human immune system, to test the anti-cancer immunotherapy.

The work was directed by John McCormick, PhD, an Associate Professor in the Department of Microbiology and Immunology and Scientist at the Lawson Health Research Institute. "Our team has been studying these bacterial toxins called 'superantigens' for their role in bacterial infections. But we are now utilizing the power of these toxins to re-direct the immune system to go after cancer cells."

McCormick says their research provides important pre-clinical evidence that this may work in humans. "This work represents a 'next-generation immunotoxin' that we hope will eventually lead to a new class of cancer therapeutic."

The research was funded by the Canadian Institutes of Health Research. Jennifer Dixon Pittaro, Peter Bastedo, David Hess and Mansour Haeryfar all contributed to the paper entitled "Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen."

McCormick and his colleagues have now received a new grant from the Cancer Research Society to develop different toxin and antibody combinations to fight other types of cancer.

Kathy Wallis | Eurek Alert!
Further information:
http://www.uwo.ca

Further reports about: bacteria bacterial colon fight grow immune immunotoxin infections toxins

More articles from Health and Medicine:

nachricht In mice, vaccine stops urinary tract infections linked to catheters
18.09.2014 | Washington University School of Medicine

nachricht NAMS issues first comprehensive recommendations on care of women at menopause and beyond
17.09.2014 | The North American Menopause Society (NAMS)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

"Start-ups and spin-offs funding – Public and private policies", 14th October 2014

12.09.2014 | Event News

BALTIC 2014: Baltic Sea Geologists meet in Warnemünde

03.09.2014 | Event News

IT security in the digital society

27.08.2014 | Event News

 
Latest News

No sedative necessary: Scientists discover new “sleep node” in the brain

19.09.2014 | Life Sciences

Sensing Neuronal Activity With Light

19.09.2014 | Life Sciences

Miranda: An Icy Moon Deformed by Tidal Heating

19.09.2014 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>